Ítem
Acceso Abierto

Sobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de Bogotá

Mostrar el registro sencillo de la publicación
dc.contributor.advisorGarcés Sterling, Sandra Patricia
dc.contributor.advisorVelez Van Meerbeke, Alberto Francisco
dc.creatorCastelblanco-Coy, Lizeth Johana
dc.creator.degreeEspecialista en Pediatríaspa
dc.creator.degreetypeFull timespa
dc.date.accessioned2021-02-23T21:21:00Z
dc.date.available2021-02-23T21:21:00Z
dc.date.created2021-02-05
dc.descriptionIntroducción: La Leucemia Linfoide Aguda (LLA) es el cáncer más común en niños. Existen estudios de sobrevida y sus factores asociados en países de altos ingresos, pero pocos en países de ingreso mediano-alto, como Colombia. Objetivo: Establecer la sobrevida global y analizar los factores que inciden en la misma. Materiales y métodos: Estudio descriptivo de serie de casos de niños con LLA tratados en la Fundación Cardioinfantil 2007-2017. Se obtuvo datos de 72 pacientes. Se obtuvo información demográfica, paraclínica, del tratamiento recibido y desenlace en una base de datos. Se estableció la sobrevida global y posteriormente se realizó un análisis con modelo de cohortes para establecer las diferentes variables que la afectaban. Las curvas de sobrevida fueron estimadas con el método Kaplan-Meier. Los factores encontrados se evaluaron mediante el modelo de riesgos proporcionales de Cox. Se obtuvo aprobación del comité de ética. Resultados: La sobrevida a 10 años fue de 73,9%. La LDH al diagnóstico (P= 0,012), clasificación del riesgo (P= 0,013), tratamiento recibido (P= 0,009), no adherencia al tratamiento (P=0,000), necesidad de segundo esquema de tratamiento por recaída (P=0,000) y en el análisis multivariado, la procedencia (P=0,037) la impactaron negativamente. Conclusiones: La sobrevida global es equiparable con centros de referencia nacionales en cáncer infantil. Se requiere la realización de estudios prospectivos en donde se identifiquen nuevos factores de riesgo que expliquen la falla al tratamiento de la LLA pediátrica y que permitan diseñar protocolos de tratamiento cada vez más específicos y tendientes a mejorar la sobrevida de los pacientes.spa
dc.description.abstractIntroduction: Acute Lymphoblastic Leukemia (ALL) is the most common type of cancer in children. There are several studies in high-income countries regarding survival rate and its associated factors, but studies are lacking in upper-middle income countries, like Colombia. Objective: To establish the overall survival rate and to analyze its associated factors that negatively impact it. Methods: A descriptive case study of children with Acute Lymphoblastic Leukemia who were treated at Fundación Cardioinfantil from 2007-2017 was carried out. Data obtained from case records of 72 patients was analyzed. Information regarding demographic profile, labs on diagnosis, treatment, and outcome were recorded on a database. Overall survival rate was determined and a cohort analysis was used to establish which factors affected it. Survival curves were estimated using the Kaplan–Meier method. Associated factors were assessed using Cox Proportional Hazards Regression Analysis. The study was approved by the ethics committee. Results: Overall 10-year survival rate was 73.9%. LDH on diagnosis (P= 0,012), risk stratification (P= 0,013), treatment administered (P= 0,009), non adherence to treatment (P=0,000), second course of treatment due to relapse (P=0,000) and on multivariate analysis urban areas of origin (P=0,037) negatively impacted survival rate. Conclusions: Overall survival rate is comparable to national pediatric cancer reference centers. Future prospective studies that recognize other associated factors that potentially explain treatment failure are needed. This will enable new randomized controlled trials that may evaluate different and more targeted treatment protocols that Will improve overall survival rates in children with ALL.spa
dc.format.extent61spa
dc.format.mimetypeapplication/pdf
dc.geoLocationBogotá, Colombiaspa
dc.identifier.doihttps://doi.org/10.48713/10336_30971
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/30971
dc.language.isospaspa
dc.publisherUniversidad del Rosariospa
dc.publisher.departmentEscuela de Medicina y Ciencias de la Saludspa
dc.publisher.programEspecialización en Pediatríaspa
dc.rightsAtribución-SinDerivadas 2.5 Colombiaspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.spa
dc.rights.urihttp://creativecommons.org/licenses/by-nd/2.5/co/
dc.source.bibliographicCitation1. Fondo Colombiano de Enfermedades de Alto Costo. Generalidades Cáncer Pediátrico. In: Situación del Cáncer en Colombia 2015. Fondo Colombiano de Enfermedades de Alto Costo; 2015. p. 73–90.spa
dc.source.bibliographicCitation2. Bravo LE, García LS, Collazos P, Aristizabal P, Ramírez O. Descriptive epidemiology of childhood cancer in Cali, Colombia 1977-2011. Colomb Med. 2013;44(3):155–64.spa
dc.source.bibliographicCitation3. Coebergh JWW, Reedijk AMJ, de Vries E, Martos C, Jakab Z, Steliarova-Foucher E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2019–36.spa
dc.source.bibliographicCitation4. Horibe K, Saito AM, Takimoto T, Tsuchida M, Manabe A, Shima M, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): Based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol. 2013;98(1):74–88.spa
dc.source.bibliographicCitation5. Ries L, Smith M, Gurney J, Linet M, Tamra T, Young J, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. 1999. p. 1–182.spa
dc.source.bibliographicCitation6. Miller R. Persons with exceptionally high risk of leukemia. Cancer Res. 1967;27:2420–2423.spa
dc.source.bibliographicCitation7. Belson M, Kingsley B, Holmes A. Risk Factors for Acute Leukemia in Children: A Review. Environ Health Perspect. 2007;115(1):138–45.spa
dc.source.bibliographicCitation8. Gardner MJ. Father’s occupational exposure to radiation and the raised level of childhood leukemia near the Sellafield nuclear plant. Environ Health Perspect. 1991;94:5–7.spa
dc.source.bibliographicCitation9. McKinney PA, Alexander FE, Cartwright RA, Parker L. Parental Occupations Of Children With Leukaemia In West Cumbria, North Humberside, And Gateshead. Vol. 302, BMJ: British Medical Journal. BMJ; 1991. p. 681–7.spa
dc.source.bibliographicCitation10. Shu XO, Stewart P, Wen W, Han D, Potter JD, Buckley JD, et al. Parental Occupational Exposure to Hydrocarbons and Risk of Acute Lymphocytic Leukemia in Offspring Parental Occupational Exposure to Hydrocarbons and Risk of Acute Lymphocytic Leukemia in Offspring 1. Cancer Epidemiol biomarkers Prev. 1999;8:783–91.spa
dc.source.bibliographicCitation11. Freedman DM, Stewart P, Kleinerman RA, Wacholder S, Hatch EE, Tarone RE, et al. Household solvent exposures and childhood acute lymphoblastic leukemia. Am J Public Health. 2001;91(4):564–7.spa
dc.source.bibliographicCitation12. Pardo C, Cendales R. Incidencia, mortalidad y prevalencia de Cáncer en Colombia 2007-2011. 1st ed. Pardo C, Cendales R, editors. Vol. 1, Instituto Nacional De Cancerologia. Bogotá D.C.; 2015. 13–147 p.spa
dc.source.bibliographicCitation13. Vera AM, Pardo C, Duarte MC, Suárez A. Experiencia en el análisis de la mortalidad por leucemia aguda pediátrica en el Instituto Nacional de Cancerología. Biomédica. 2012;32(3):355–64.spa
dc.source.bibliographicCitation14. Linares Ballesteros A, Torres Amaya AM, Molina León HF, Vizcaíno Valderrama MP, Martínez Beltrán L, de Los Reyes Valencia I del C, et al. Guía de Práctica Clínica para la detección oportuna, diagnóstico y seguimiento de leucemia linfoide aguda y leucemia mieloide aguda en niños, niñas y adolescentes. Ministerio de Salud y Protección Social - Colciencias; 2013. p. 4–83.spa
dc.source.bibliographicCitation15. World Health Organization. Global Cancer Observatory [Internet]. International Agency for Research on Cancer. 2020 [cited 2021 Feb 4]. Available from: https://gco.iarc.fr/spa
dc.source.bibliographicCitation16. Bosetti C, Bertuccio P, Chatenoud L, Negri E, Levi F, La Vecchia C. Childhood cancer mortality in Europe, 1970-2007. Eur J Cancer. 2010;46(2):384–94.spa
dc.source.bibliographicCitation17. Hunger SP, Winick NJ, Sather HN, Carroll WL. Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: When do we say enough? Pediatr Blood Cancer. 2005;45(7):876–80.spa
dc.source.bibliographicCitation18. Magrath I, Steliarova-foucher E, Epelman S, Ribeiro RC, Harif M, Li C, et al. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013;14:e104–16.spa
dc.source.bibliographicCitation19. Wayne AS, Reaman GH, Helman LJ. Progress in the curative treatment of childhood hematologic malignancies. J Natl Cancer Inst. 2008;100(18):1271–3.spa
dc.source.bibliographicCitation20. Pui C-H, Carroll WL, Meshinchi S, Arceci RJ. Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update. J Clin Oncol. 2011;29(5):551–65.spa
dc.source.bibliographicCitation21. Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60(1):4–12.spa
dc.source.bibliographicCitation22. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009;45(6):992–1005.spa
dc.source.bibliographicCitation23. Lightfoot TJ, Johnston WT, Simpson J, Smith AG, Ansell P, Crouch S, et al. Survival from childhood acute lymphoblastic leukaemia: The impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263–9.spa
dc.source.bibliographicCitation24. Lustosa de Sousa DW, de Almeida Ferreira FV, Cavalcante Félix FH, de Oliveira Lopes MV. Acute lymphoblastic leukemia in children and adolescents: Prognostic factors and analysis of survival. Rev Bras Hematol Hemoter. 2015;37(4):223–9.spa
dc.source.bibliographicCitation25. Piñeros M, Pardo C, Otero J, Suárez A, Vizcaíno M, Alvarez VH, et al. Protocolo de vigilancia en salud pública de las leucemias agudas pediátricas. Instituto Nacional de Salud Instituto Nacional de Cancerología Ministerio de la Protección social. 2007. p. 1–13.spa
dc.source.bibliographicCitation26. Sarmiento-Urbina IC, Linares-Ballesteros A, Contreras-Acosta A, Cabrera-Bernal EV, Pardo-González CA, Uribe-Botero GI, et al. Resultados del Protocolo ACHOP 2006 en los niños con leucemia linfoblástica aguda en la Fundación HOMI Hospital de la Misericordia de Bogotá, en el periodo 2007 - 2012. IATREIA. 2019;32(2):71–81.spa
dc.source.bibliographicCitation27. Cuenta de Alto Costo. Situación del cáncer de la población atendida en el SGSSS en Colombia 2015. Cuenta Alto Costo. 2016;1(1):35–330.spa
dc.source.bibliographicCitation28. Nordlund J, Syvänen AC. Epigenetics in pediatric acute lymphoblastic leukemia. Semin Cancer Biol. 2018;51:129–38.spa
dc.source.bibliographicCitation29. Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975–83.spa
dc.source.bibliographicCitation30. Lanzkowsky P. Leukemias. In: Lanzkowsky P, editor. Manual of Pediatric Hematology and Oncology. 5th ed. San Diego, California: ElSevier; 2011. p. 518–66.spa
dc.source.bibliographicCitation31. Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62(1):61–73.spa
dc.source.bibliographicCitation32. Instituto Nacional de Cancerología. Protocolo de tratamiento de Leucemia Linfoblástica Aguda LLA - INC 2012 basado en LLA - PINDA IC 2009. 2012. p. 1–42.spa
dc.source.bibliographicCitation33. Erker C, Yan K, Zhang L, Bingen K, Flynn KE, Panepinto J. Impact of pediatric cancer on family relationships. Cancer Med. 2018;7(5):1680–8.spa
dc.source.bibliographicCitation34. Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi R. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol. 2017;83(12):2605–14.spa
dc.source.bibliographicCitation35. Pui C-H, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov. 2007;6(2):149–65.spa
dc.source.bibliographicCitation36. Turcotte LM, Liu Q, Yasui Y, Arnold MA, Hammond S, Howell RM, et al. Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970-2015. JAMA - J Am Med Assoc. 2017;317(8):814–24.spa
dc.source.bibliographicCitation37. Gaudichon J, Jakobczyk H, Debaize L, Cousin E. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues. Blood Rev. 2019;36:40–56.spa
dc.source.bibliographicCitation38. Irestorm E, Olsson IT, Johansson B, Øra I. Cognitive fatigue in relation to depressive symptoms after treatment for childhood cancer. BMC Psychol. 2020;8(31):1–9.spa
dc.source.bibliographicCitation39. Steur LMH, Grootenhuis MA, Van Someren EJW, Van Eijkelenburg NKA, Van der Sluis IM, Dors N, et al. High prevalence of parent-reported sleep problems in pediatric patients with acute lymphoblastic leukemia after induction therapy. Pediatr Blood Cancer. 2020;67(4):e28165.spa
dc.source.bibliographicCitation40. Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Blood. 2008;111(12):5515–23.spa
dc.source.bibliographicCitation41. The World Bank. World Bank Country and Lending Groups [Internet]. Working for a World Free of Poverty. 2020 [cited 2021 Feb 4]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519spa
dc.source.bibliographicCitation42. Bravo L, Collazos T, García L, Gutiérrez A, Carrascal E. Cáncer infantil en Cali, Colombia, 1994-2003. Registro Poblacional de Cáncer en Cali. Cali: Camilo Torres Serna y Cia S.C.S; 2009.spa
dc.source.bibliographicCitation43. Abboud MR, Ghanem K, Muwakkit S. Acute lymphoblastic leukemia in low and middle-income countries: disease characteristics and treatment results. Curr Opin Oncon. 2014;26(6):650–5.spa
dc.source.bibliographicCitation44. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study. Blood. 2010;115(16):1–24.spa
dc.source.bibliographicCitation45. Rengifo LA, Suárez A. Protocolo de tratamiento de leucemia linfoblástica aguda LLA-INC 2012. Basado en LLA-PINDA 2009. Inst Nac Cancerol. 2012;1–42.spa
dc.source.bibliographicCitation46. Campbell M, Luis C, Riccheri C, Janic D, Jazbec J, Kaiserova E, et al. Protocolo de estudio y tratamiento de la leucemia linfoblástica infantil. ALL IC-BFM 2009. Santiago de Chile: Ministerio de Salud de Chile; 2009. p. 1–174.spa
dc.source.bibliographicCitation47. Ospina-Romero M, Portilla CA, Bravo LE, Ramirez O. Caregivers’ self-reported absence of social support networks is related to treatment abandonment in children with cancer. Pediatr Blood Cancer. 2016;63:825–31.spa
dc.source.bibliographicCitation48. Shen S, Cai J, Chen J, Xue H, Pan C, Gao Y, et al. Long-term results of the risk-stratified treatment of childhood acute lymphoblastic leukemia in China. Hematol Oncol. 2018;36(July):679–88.spa
dc.source.bibliographicCitation49. Downing JR, Shannon KM. Acute leukemia: A pediatric perspective. Cancer Cell. 2002;2(6):437–45spa
dc.source.bibliographicCitation50. Linet MS, Ries LAG, Smith MA, Robert E, Devesa SS. Cancer Surveillance Series: Recent Trends in Childhood Cancer Incidence and Mortality in the United States. J Natl Cancer Institute. 1999;91(12):1051–8.spa
dc.source.bibliographicCitation51. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.spa
dc.source.bibliographicCitation52. Hutter JJ. Childhood Leukemia. Pediatr Rev. 2010;31(6):234–41.spa
dc.source.bibliographicCitation53. Hunger S, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373(16):1541–52.spa
dc.source.bibliographicCitation54. Hoshino A, Okuno Y, Migita M, Ban H, Yang X, Kiyokawa N, et al. X-Linked Agammaglobulinemia Associated with B-Precursor Acute Lymphoblastic Leukemia. J Clin Immunol. 2015;35(2):108–11.spa
dc.source.bibliographicCitation55. Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014;7:55–66spa
dc.source.bibliographicCitation56. Stieglitz E, Loh ML. Genetic predispositions to childhood leukemia. Ther Adv Hematol. 2013;4(4):270–90.spa
dc.source.bibliographicCitation57. Ratnaparkhe M, Hlevnjak M, Kolb T, Jauch A, Maass KK, Devens F, et al. Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. Leukemia. 2017;31(10):2048–56.spa
dc.source.bibliographicCitation58. Varon R, Reis A, Henze G, Einsiedel HG V., Sperling K, Seeger K. Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res. 2001;61(9):3570–2.spa
dc.source.bibliographicCitation59. Adams M, Jenney M, Lazarou L, White R, Birdsall S, Staab T, et al. Acute Myeloid Leukaemia after Treatment for Acute Lymphoblastic Leukaemia in Girl with Bloom Syndrome. J Genet Syndr Gene Ther. 2014;4(8):1–12spa
dc.source.bibliographicCitation60. Werner-Favre C, Wyss M, Cabrol C, Felix F, Guenin R, Laufer D. Cytogenetic study in a mentally retarded child with Bloom syndrome and acute lymphoblastic leukemia. Am J Med Genet. 1984;18(2):215–221spa
dc.source.bibliographicCitation61. Wang Y, Sun Z, Xu Y. Carriage of NBN polymorphisms and acute leukemia risk. Int J Clin Exp Med. 2015;8(3):3769–76.spa
dc.source.bibliographicCitation62. Alter BP. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol. 2014;27(3–4):214–21.spa
dc.source.bibliographicCitation63. Online Mendelinan Inheritance in Man. Fanconi Anemia [Internet]. OMIM. 2019 [cited 2020 Feb 24]. Available from: https://omim.org/search/?index=entry&start=1&limit=10&sort=score+desc%2C+prefix_sort+desc&search=Fanconi+anemiaspa
dc.source.bibliographicCitation64. Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, et al. TP53 germline variations influence the predisposition and prognosis of b-cell acute lymphoblastic leukemia in children. J Clin Oncol. 2018;36(6):591–9.spa
dc.source.bibliographicCitation65. Zawitkowska J, Odoj T, Drabko K, Zaucha-Prazmo A, Rudnicka J, Romiszewski M, et al. Outcome of acute lymphoblastic leukemia in children with down syndrome-Polish pediatric leukemia and lymphoma study group report. Pediatr Hematol Oncol. 2017;34(4):1–8.spa
dc.source.bibliographicCitation66. Xu H, Yang W, Perez-Andreu V, Devidas M, Fan Y, Cheng C, et al. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst. 2013;105(10):733–42.spa
dc.source.bibliographicCitation67. Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146–62.spa
dc.source.bibliographicCitation68. Kinlen L. Epidemiological evidence for an infective basis in childhood leukaemia. Br J Cancer. 1995;71:1–5.spa
dc.source.bibliographicCitation69. Bartenhagen C, Fischer U, Korn K, Pfister SM, Gombert M, Chen C, et al. Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing. Haematologica. 2017;102(5):e179–83.spa
dc.source.bibliographicCitation70. Martín-Lorenzo A, Hauer J, Vicente-Dueñas C, Auer F, González-Herrero I, García-Ramírez I, et al. Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility. Cancer Discov. 2015;5(12):1328–43.spa
dc.source.bibliographicCitation71. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6(3):193–203spa
dc.source.bibliographicCitation72. Greaves MF, Alexander FE. An infectious etiology for common acute lymphoblastic leukemia in childhood? Leukemia. 1993 Mar;7(3):349–60.spa
dc.source.bibliographicCitation73. Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon S-M, et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol. 2015;16(7):766–74spa
dc.source.bibliographicCitation74. Baljevic M, Jabbour E, O’Brien S, Kantarjian H. Acute Lymphoblastic Leukemia. In: Kantarjian H, Wolff R, editors. The MD Anderson Manual of Medical Oncology. 3rd ed. New York City: McGraw-Hill; 2016.spa
dc.source.bibliographicCitation75. Margolin JF, Steuber P, Poplack DG. Acute Lymphoblastic Leukemia. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott-Williams and Wilkins; 2006.spa
dc.source.bibliographicCitation76. Robazzi TCMV, Silva LR, Mendonça N, Barreto JHS. Gastrointestinal manifestations as initial presentation of acute leukemias in children and adolescents. Acta Gastroenterol Latinoam. 2008;38(2):126–32.spa
dc.source.bibliographicCitation77. Stephanos K, Picard L. Pediatric Oncologic Emergencies. Emerg Med Clin N Am. 2018;36(3):527–35.spa
dc.source.bibliographicCitation78. Margolin J, Rabin K, Steuber P, Poplack D. Acute lymphoblastic leukemia. In: Pizzo P, Poplack D, editors. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott, Williams and Wilkins; 2011. p. 518–65spa
dc.source.bibliographicCitation79. Hangai M, Watanabe K, Shiozawa R, Hiwatari M, Ida K, Takita J. Relapsed acute lymphoblastic leukemia with unusual multiple bone invasions: A case report. Oncol Lett. 2014;7(4):991–3.spa
dc.source.bibliographicCitation80. Sherief LM, Azab SF, Zakaria MM, Kamal M, Aly MAE, Ali A, et al. Renal presentation in pediatric acute leukemia: Report of 2 cases. Med (United States). 2015;94(37):37–40.spa
dc.source.bibliographicCitation81. Cho-Vega JH, Medeiros LJ, Prieto VG, Vega F. Leukemia cutis. Am J Clin Pathol. 2008;129(1):130–42.spa
dc.source.bibliographicCitation82. Jarošová M, Holzerová M, Jedličková K, Mihál V, Zuna J, Starý J, et al. Importance of using comparative genomic hybridization to improve detection of chromosomal changes in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2000;123(2):114–22.spa
dc.source.bibliographicCitation83. Mrózek K, Harper DP, Aplan PD. Cytogenetics and Molecular Genetics of Acute Lymphoblastic Leukemia. Hematol Oncol Clin North Am. 2009;23(5):991–1010.spa
dc.source.bibliographicCitation84. Sutor A, Mall V, Thomas K. Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol. Klin Pädiatrie. 1999 Jul 13;211(04):201–4spa
dc.source.bibliographicCitation85. Lauer S, Kirchner P, Camitta B. Identification of leukemic cells in the cerebrospinal fluid from children with acute lymphoblastic leukemia: advances and dilemmas. Am J Pediatr Hematol Oncol. 1989;11(1):64–73.spa
dc.source.bibliographicCitation86. Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, et al. Low leucocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993;329(5):314–9.spa
dc.source.bibliographicCitation87. McIntosh S, Ritchey A. Diagnostic problems in cerebrospinal fluid of children with lymphoid malignancies. Am J Pediatr Hematol Oncol. 1986;8(1):28–31spa
dc.source.bibliographicCitation88. Ingram LC, Fairclough DL, Furman WL, Sandlund JT, Kun LE, Rivera GK, et al. Cranial nerve palsy in childhood acute lymphoblastic leukemia and non‐Hodgkin’s lymphoma. Cancer. 1991;67(9):2262–8.spa
dc.source.bibliographicCitation89. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18–24.spa
dc.source.bibliographicCitation90. Gilchrist GS, Tubergen DG, Sather HN, Coccia PF, O’Brien RT, Waskerwitz MJ, et al. Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Childrens Cancer Group report. J Clin Oncol. 1994;12(12):2594–600.spa
dc.source.bibliographicCitation91. Tubergen DG, Cullen JW, Boyett JM, Gilchrist GS, O’Brien RT, Coccia PF, et al. Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: a Childrens Cancer Group study. J Clin Oncol. 1994;12(2):273–8.spa
dc.source.bibliographicCitation92. Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003 May 1;21(9):1798–809.spa
dc.source.bibliographicCitation93. Bennett J, Catovsky D, Daniel M-T, Flandrin G, Galton D, Gralnick H, et al. (FAB Co- operative Group): Proposals for the classification of the acute leukaemias. Br J Haematol. 1976;33:451.spa
dc.source.bibliographicCitation94. Bennett J, Catovsky D, Daniel M-T, Flandrin G, Galton D, Gralnick H, et al. (FAB Co- operative Group): The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol. 1981;47:553.spa
dc.source.bibliographicCitation95. Linares-Ballesteros A. Guía de Práctica Clínica para la detección oportuna, diagnóstico y seguimiento de leucemia linfoide aguda y leucemia mieloide aguda en niños, niñas ya dolescentes. Ministerio de Salud y Protección Social; 2013.spa
dc.source.bibliographicCitation96. Vizcaino M, Lopera J, Martínez L, De los Reyes I, Linares A. Clinical practice guidelines for early detection, diagnosis, treatment and monitoring of acute lymcytic leukemia in children and teenagers in a developing country. Pediatr Infect Dis Open Access. 2016;1(4):25.spa
dc.source.bibliographicCitation97. Langebrake C, Reinhardt D, Ritter J. Minimising the long-term adverse effects of childhood leukaemia therapy. Drug Saf. 2002;25(15):1057–77.spa
dc.source.bibliographicCitation98. Leung W, Hudson M, Zhu Y, Rivera GK, Ribeiro RC, Sandlund JT, et al. Late effects in survivors of infant leukemia. Leukemia. 2000;14(7):1185–90.spa
dc.source.bibliographicCitation99. Zawitkowska J, Lejman M, Zaucha-Prazmo A, Drabko K, Plonowski M, Bulsa J, et al. Grade 3 and 4 Toxicity Profiles During Therapy of Childhood Acute Lymphoblastic Leukemia. In Vivo (Brooklyn). 2019;33:1333–9.spa
dc.source.bibliographicCitation100. Krull KR. Dexamethasone and neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(3):e28118.spa
dc.source.bibliographicCitation101. Mulhern R, Kovnar E, Langston J, Carter M, Fairclough D, Leigh L, et al. Long-term survivors of leukemia treated in infancy: factors associated with neuropsychologic status. J Clin Oncol. 1992;(10):1095–1102.spa
dc.source.bibliographicCitation102. Mulhern R, Fairclough D, Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol1. 1991;(9):1348–1356.spa
dc.source.bibliographicCitation103. Tanner J, Davies P. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107:317–329.spa
dc.source.bibliographicCitation104. Marshall W, Tanner J. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;13–23.spa
dc.source.bibliographicCitation105. Marshall W, Tanner J. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;291–303.spa
dc.source.bibliographicCitation106. Schmiegelow K, Müller K, Mogensen SS, Mogensen PR, Wolthers BO, Stoltze UK, et al. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Research. 2017;6(444):1–14.spa
dc.source.bibliographicCitation107. Halsey C, Buck G, Richards S, Vargha-khadem F, Hill F, Gibson B. The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J Hematol Oncol. 2011;4(1):42.spa
dc.source.bibliographicCitation108. Waber DP, Mccabe M, Sebree M, Forbes PW, Adams H, Alyman C, et al. Neuropsychological Outcomes of a Randomized Trial of Prednisone Versus Dexamethasone in Acute Lymphoblastic Leukemia: Findings From Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer. 2013;60:1785–91.spa
dc.source.bibliographicCitation109. Sun Y, Long S, Liu W. Observation of the molecular genetics among children with acute lymphoblastic leukemia: A retrospective study based on the SEER database. Medicine (Baltimore). 2020;99(21):e20009.spa
dc.source.bibliographicCitation110. Lund B, Asberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H, et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2011;56:551–9.spa
dc.source.bibliographicCitation111. Paulsson K, Lilljebjörn H, Biloglav A, Olsson L, Rissler M, Castor A, et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet. 2015;47(6):672–6.spa
dc.source.bibliographicCitation112. Pui C, Rebora P, Schrappe M, Attarbaschi A, Baruchel A. Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. J Clin Oncol. 2019;37(10):770–9.spa
dc.source.bibliographicCitation113. Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic mutations in infant MLL -rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330–7.spa
dc.source.bibliographicCitation114. Schultz K, Carroll A, Heeerema N, Bowman W, Slayton W, Sather H, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031. Leukemia. 2014;28(7):1467–71.spa
dc.source.bibliographicCitation115. Johnston WT, Lightfoot TJ, Simpson J, Roman E. Childhood cancer survival: A report from the United Kingdom Childhood Cancer Study. Cancer Epidemiol. 2010;34(6):659–66.spa
dc.source.bibliographicCitation116. Barr RD, Klussman FA, Baez F, Bonilla M, Moreno B, Navarrete M, et al. Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): A Model for Sustainable Development in Pediatric Oncology. Pediatr Blood Cancer. 2014;61:345–54.spa
dc.source.bibliographicCitation117. Suarez A, Piña M, Nichols-Vinueza DX, Lopera J, Rengifo L, Mesa M, et al. A Strategy to Improve Treatment-Related Mortality and Abandonment of Therapy for Childhood ALL in a Developing Country Reveals the Impact of Treatment Delays. Pediatr Blood Cancer. 2015;62(March):1395–402.spa
dc.source.bibliographicCitation118. Freeman D. Applied categorical data analysis. New York: Dekker, Inc; 1987.spa
dc.source.bibliographicCitation119. RAE. Real Academia Española [Internet]. 2018 [cited 2018 Sep 21]. Available from: http://dle.rae.es/?id=XlApmpespa
dc.source.bibliographicCitation120. De la Asociación Médica Mundial sobre principios éticos para las investigaciones médicas en seres humanos. Declaración de Helsinki. 59a Asamblea General. 2008.spa
dc.source.bibliographicCitation121. Ministerio de Salud. Resolución 8430 de 1993. Colombia; 1993 p. 1–19.spa
dc.source.bibliographicCitation122. Congreso de Colombia. Ley estatutaria No. 1581. 17 Octubre 2012. Colombia; 2012 p. 1–301.spa
dc.source.bibliographicCitation123. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study. Blood. 2010;115(16):3206–14.spa
dc.source.bibliographicCitation124. Campbell M. ALL IC-BFM 2009 A Randomized Trial of the I-BFM-SG for the Management of Childhood non-B Acute Lymphoblastic Leukemia. 2009. 178 p.spa
dc.source.bibliographicCitation125. Malo D, Pulido A. Infección Respiratoria Aguda, Colombia 2017. Instituto Nacional de Salud. 2017. p. 1–31.spa
dc.source.bibliographicCitation126. Bartenhagen C, Fischer U, Korn K, Pfister S, Gombert M, Chen C, et al. Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing. Haematologica. 2017;102:e179.spa
dc.source.bibliographicCitation127. Lightfoot TJ, Johnston WT, Simpson J, Smith AG, Ansell P, Crouch S, et al. Survival from childhood acute lymphoblastic leukaemia: The impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263–9.spa
dc.source.bibliographicCitation128. Pui C-H, Dodge RK, Dahl G V, Rivera G, Look AT, Kalwinsky D, et al. Serum Lactic Dehydrogenase Level Has Prognostic Value in Childhoold Acute Lymphoblastic Leukemia. Blood. 1985;66(4):778–82.spa
dc.source.bibliographicCitation129. Murali N, Swamy M, Prasad H, Saha D, Kini J, Kumar N. Significance of serum lactate dehydrogenase in childhood acute Lymphoblastic Leukaemia. J Clin Diagnostic Res. 2017;11(11):XC01–2.spa
dc.source.bibliographicCitation130. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus. Br J Haematol. 2010;149(4):578–86.spa
dc.source.bibliographicCitation131. Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23(31):7958–66.spa
dc.source.bibliographicCitation132. Ramot B, Magrath I. Hypothesis: the environment is a major determinant of the immunological sub-type of lymphoma and acute lymphoblastic leukaemia in children. Br J Haematol. 1982;50(2):183–9.spa
dc.source.bibliographicCitation133. Filippini T, Hatch EE, Rothman KJ, Heck JE, Park AS, Crippa A, et al. Association between Outdoor Air Pollution and Childhood Leukemia: A Systematic Review and Dose-Response Meta-Analysis. Environ Health Perspect. 2019;127(4):46002.spa
dc.source.bibliographicCitation134. Wakeford R. Childhood leukemia following medical diagnostic exposre to ionizing radiation in utero or after birth. Radiat Prot Dosimetry. 2008;132(2):166–74.spa
dc.source.bibliographicCitation135. Cangerana F, Mirra A, Dias de Oliveira M do R, de Assunção JV. Environmental Risk Factors and Acute Lymphoblastic Leukaemia in Childhood. Rev Cienc Salud. 2017;15(1):129–44.spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subjectLeucemia Linfoide Aguda (LLA) en niñosspa
dc.subjectEstudios de sobrevida a la LLA en países de ingreso mediano-altospa
dc.subjectEstimación de curvas de sobrevida con el método Kaplan-Meierspa
dc.subject.ddcEnfermedadesspa
dc.subject.keywordAcute Lymphoid Leukemia (ALL) in Childrenspa
dc.subject.keywordSurvival studies for ALL in upper-middle-income countriesspa
dc.subject.keywordEstimation of survival curves with the Kaplan-Meier methodspa
dc.titleSobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de Bogotáspa
dc.title.TranslatedTitleSurvival and associated factors in children with Acute Lymphoid Leukemia in a reference center in Bogotáspa
dc.typebachelorThesiseng
dc.type.documentDescriptivo observacional retrospectivospa
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTrabajo de gradospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
CastelblancoCoy-Lizeth-Johana-2021.pdf
Tamaño:
812.56 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Especialización en Pediatría